Destination
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan Stanley (MS) analysts.Read more... [...]

Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.Read more... [...]

Match Score: 177.10

Destination
Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next

Hims & Hers (HIMS) is expanding its playbook across the Atlantic — the U.S.-based telehealth company announced Tuesday that it will acquire European telehealth platform Zava. The acquisition gro [...]

Match Score: 176.54

Destination
Hims & Hers stock tumbles as the FDA issues a warning about 'unapproved' weight loss drugs

Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company braces for big regulatory shifts in the weight-loss drug industry.Read more. [...]

Match Score: 131.30

Destination
Hims & Hers strikes a deal with Novo Nordisk to sell Wegovy — and the stock soars 28%

Telehealth company Hims & Hers (HIMS) announced Tuesday that it will begin selling Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy.Read more... [...]

Match Score: 124.84

Destination
The best smart scales for 2025

The New Year is here and there’s no better time to kickstart those health and fitness goals. Whether you’re looking to shed a few holiday pounds, track your muscle gains or simply stay on top of a [...]

Match Score: 88.82

Destination
Roche says it will invest $50 billion in the U.S. as tariff fears hit pharma

With threats of tariffs hanging over the pharmaceutical industry, Switzerland’s Roche announced on Tuesday that it will invest $50 billion in the United States over the next five years, expanding it [...]

Match Score: 68.56

Destination
Hims and Hers reveal cyberattack — customer support system hacked and personal info stolen, here's what we know

At least 500 people were affected in breach at Hims and Hers. [...]

Match Score: 67.79

qz
Hims & Hers stock jumps 14% after FDA schedules peptide compounding review

The FDA will convene an outside panel in July to weigh compounding eligibility for 7 peptides, a category Hims & Hers has been positioning to enter [...]

Match Score: 67.17

qz
Hims & Hers Advances a Consumer-Centric Digital Health Platform

HIMS is broadening its digital-first platform with Labs, hormone therapy and weight-loss programs as it scales personalized care globally. [...]

Match Score: 63.23